CD69 and systemic lupus erythematosus: A similar pattern was seen for CD19+CD20+CD27– naïve B cells (−61.2% versus −50.0%; P = 0.004; Figure 1D), CD19+CD20–CD27bright plasmablasts (−44.9% versus −33.3%; P = 0.011; Figure 1G), and CD19+CD20–CD138+ long-lived plasma cells (−48.2% versus −37.1%; P = 0.024; Figure 1F), as well as in numerical but not statistically significant terms for CD19+CD20+CD69+ activated B cells (−43.0% versus −34.4%; P = 0.300; Figure 1C) and CD19+CD27brightCD38bright SLE-associated plasma cells (−38.9% versus −28.9%; P = 0.148; Figure 1H).